APIM THERAPEUTICS IS A BIOTECHNOLOGY COMPANY DEDICATED TO THE DEVELOPMENT OF NOVEL ANTI-CANCER AGENTS TARGETING DNA REPAIR AND CELL CYCLE CONTROL

At APIM THERAPEUTICS AS we focus on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. Our approach is based on targeting PCNA, a “hub” protein regulating cell responses to pathological (cancer) and pharmacological (chemotherapy) stress. Through development of innovative peptide drugs which contain a novel PCNA-interacting Stress Switch Peptide Motif termed APIM, the company offers a unique physiological intervention point allowing cancer-specific tumor cell elimination.

 

DRUG PIPELINE

Drug PipelineAPIM Therapeutics AS is developing a pipeline of peptide drugs that target PCNA-dependent stress responses in cancer cells. Our lead compound, ATX-101, has shown proof-of-concept in multiple preclinical in vitro and in vivo cancer models.

Learn More

 

ABOUT US

APIM Therapeutics AS is a venture capital supported spin off from the Norwegian University of Science and Technology (NTNU) at Trondheim, Norway.

Learn More

 

APIM THERAPEUTICS SNAPSHOT

APIM Therapeutics SnapshotDownload this pdf for a short company summary.

A publication in PLoS One describing ATX-101 is available here. A recent 2-page article on the relevance of APIM's  targeted mechanism of action and bladder cancer is available here.